Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study
P Bogomolov, A Alexandrov, N Voronkova… - Journal of …, 2016 - Elsevier
Background & Aims The therapeutic option for patients with chronic hepatitis delta virus
infection (CHD) is limited to interferon alpha with rare curative outcome. Myrcludex B is a first-
in-class entry inhibitor inactivating the hepatitis B virus (HBV) and hepatitis D virus (HDV)
receptor sodium taurocholate co-transporting polypeptide. We report the interim results of a
pilot trial on chronically infected HDV patients treated with myrcludex B, or pegylated
interferon alpha (PegIFNα-2a) or their combination. Methods Twenty-four patients with CHD …
infection (CHD) is limited to interferon alpha with rare curative outcome. Myrcludex B is a first-
in-class entry inhibitor inactivating the hepatitis B virus (HBV) and hepatitis D virus (HDV)
receptor sodium taurocholate co-transporting polypeptide. We report the interim results of a
pilot trial on chronically infected HDV patients treated with myrcludex B, or pegylated
interferon alpha (PegIFNα-2a) or their combination. Methods Twenty-four patients with CHD …
